ReviewFrontiers in immunology2018
Approaches to Improve Chemically Defined Synthetic Peptide Vaccines.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Dendritic Lipopeptide Nanovaccines Orchestrate Multi-Pattern Recognition Receptors Activation and Potentiate Antitumor Immunity.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- A Reproducible Sequence-Level Strategy to Enhance Peptide Immunogenicity While Preserving Wild-Type Epitope Recognition.Antibodies (Basel, Switzerland) · 2025Article
- Characterization of Synthetic Peptides by Mass Spectrometry.Methods in molecular biology (Clifton, N.J.) · 2024Article
- In Vivo Validation of Novel SyntheticVaccines · 2023Article
- Research Progress on the Development of Porcine Reproductive and Respiratory Syndrome Vaccines.Veterinary sciences · 2023Review
- Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects.Pharmaceuticals (Basel, Switzerland) · 2023Review
- A Lysosome-Targeted Tetrazine for Organelle-Specific Click-to-Release Chemistry in Antigen Presenting Cells.Journal of the American Chemical Society · 2023Article
- Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Multiple-Allele MHC Class II Epitope Engineering by a Molecular Dynamics-Based Evolution Protocol.Frontiers in immunology · 2022Article
- Formulation and Delivery Technologies for mRNA Vaccines.Current topics in microbiology and immunology · 2022Article
- Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines.Methods in molecular biology (Clifton, N.J.) · 2022Review
- HSymM-guided engineering of the immunodominant p53 transactivation domain putative peptide antigen for improved binding to its anti-p53 monoclonal antibody.Bioorganic & medicinal chemistry letters · 2021Article
- Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naïve CD8 T cells of unexposed individuals.EBioMedicine · 2021Article
- Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies.Biomolecules · 2021Review
- Enhancing proteasomal processing improves survival for a peptide vaccine used to treat glioblastoma.Science translational medicine · 2021Article
- Challenges and perspectives for immunotherapy in oesophageal cancer: A look to the future (Review).International journal of molecular medicine · 2021Review
- Titrating Polyarginine into Nanofibers Enhances Cyclic-Dinucleotide AdjuvanticityACS biomaterials science & engineering · 2021Article
- Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer.International journal of molecular sciences · 2021Review
- Armamentarium of Cryoprotectants in Peptide Vaccines: Mechanistic Insight, Challenges, Opportunities and Future Prospects.International journal of peptide research and therapeutics · 2021Review
- Engineering Antiviral Vaccines.ACS nano · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progress made in peptide-based vaccinations to induce T-cell-dependent immune responses against cancer has invigorated the search for optimal vaccine modalities. Design of new vaccine strategies intrinsically depends on the knowledge of antigen handling and optimal epitope presentation in both major histocompatibility complex class I and -II molecules by professional antigen-presenting cells to induce robust CD8 and CD4 T-cell responses. Although there is a steady increase in the understanding of the underlying mechanisms that bridges innate and adaptive immunology, many questions remain to be answered. Moreover, we are in the early stage of exploiting this knowledge to clinical advantage. Several adaptations of peptide-based vaccines like peptide-adjuvant conjugates have been explored and showed beneficial outcomes in preclinical models; but in the clinical trials conducted so far, mixed results were obtained. A major limiting factor to unravel antigen handling mechanistically is the lack of tools to efficiently track peptide vaccines at the molecular and (sub)cellular level. In this mini-review, we will discuss options to develop molecular tools for improving, as well as studying, peptide-based vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.